Objectives: Following revascularization procedures, Vein Graft Failure (VGF) can generate complications such as repeat revascularization, myocardial infarction (MI), mortality, hospital readmission, quality of life and co-morbidities. VGF is the most common complication of Coronary Artery Bypass Grafting (CABG). Storage and flushing of the vein graft is the most critical stage of the surgery. DuraGraft is one-time intraoperative vein graft treatments that prevents VGF and reduces repeat revascularization and MI by 48% and 53% respectively. The main objective of this study is to analyze the cost effectiveness of DuraGraft in CABG in Turkey. Methods: A simple decision model was used in the study. Analyses were made from the Turkish Social Security Institution’s (SSI/SGK) perspective. Literature research and expert opinions were used to estimate the cost of CABG and complications as revascularization and myocardial infarction. The comparison was made with use and nonuse of DuraGraft. Outcome measures were taken from literature, cost data were obtained from expert views of use of resources in both CABG and treatment of complications. The results were presented as incremental cost per averted complication. Results: There were 46.956 CABG procedures performed in Turkey in 2016. Revascularization after CABG was 4,59% and experts stated that 35% of these patients undergo another CABG, with and ballon+stent applied to the other patients. MI rate after CABG was 4,44%. Cost of treatment per patient was 6.430 TRY for CABG, 1.865 TRY for balloon+stent and 8.277 TRY for MI. The incremental number of averted complications was 2.724. In terms of incremental cost effectiveness ratio, use of DuraGraft as a vein graft treatment dominated non-use and achieved better outcomes with lower cost. Conclusions: The results showed that use of DuraGraft as a vein graft treatment in CABG is a cost effective option for the Turkish SSI/SGK.